Biopharmaceutical drug development: Filgrastim (r-metHuG-CSF) use in patients with HIV infection.
Hematopoietic growth factors are well known to increase neutrophil counts and support the administration of myelotoxic and myelosuppressive therapies, especially chemotherapies. Filgrastim (r-metHuG-CSF) has been used in the setting of HIV disease to treat neutropenia and HIV-associated neutrophil defects. This article reviews the biology, product characteristics, and preclinical and clinical development of Filgrastim. Emphasis is given on the use of Filgrastim in the setting of HIV infection and AIDS.
Foote
M
M
Amgen Inc., Thousand Oaks, CA 91320-1799, USA.
Welch
W
W
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications / Q000188:drug therapy; D000818:Animals; D019380:Anti-HIV Agents / Q000009:adverse effects*; D002460:Cell Line; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D009503:Neutropenia / Q000139:chemically induced / Q000188:drug therapy*; D009504:Neutrophils / Q000187:drug effects; D011994:Recombinant Proteins
D019380:Anti-HIV Agents; D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D000069585:Filgrastim